Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis

Wood, James R.; Czaja, Albert J.; Beaver, Sandra J.; Hall, Stephen; Ginsburg, William W.; Kaufman, David K.; Markowitz, Harold

doi:10.1002/hep.1840060528

“…Long-term outcomes were luciliae occur commonly in patients with ANA-positive type 1 autoimmune hepatitis and that these serologic markers are similar between the 7 patients with anti-dsDNA by ELISA but not by the Crithidia-based assay and the 44 others but not restricted to individuals with SLE. [8][9][10] Seropositivity for anti-dsDNA by the Crithidia-based assay is less frequent than follow-up was shorter in the former group (mean follow-up, 70 { 18 mo vs. 108 { 11 mo, P Å .2).…”

Section: Aid Hepa 0004mentioning

confidence: 99%

“…8 Tsuchiya and colleagues, using an ELISA dsDNA) in antinuclear antibody (ANA)-positive type 1 autobased on a similar substrate, found anti-dsDNA in 48% of immune hepatitis, sera from 53 patients were tested by patients with autoimmune hepatitis and 17% of patients with enzyme immunosorbent assay (ELISA) and indirect immunoprimary biliary cirrhosis. 9 Testing of the same sera by an fluorescence using the Crithidia luciliae substrate.…”

mentioning

confidence: 99%

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis

Czaja

¹

,

Morshed

²

,

Parveen

³

et al. 1997

View full text Add to dashboard Cite

dsDNA were shown in 64% of patients with autoimmune To determine the significance of antibodies to singlehepatitis, 46% with cryptogenic hepatitis, and 43% with stranded (anti-ssDNA) and double-stranded DNA (antichronic hepatitis B. 8 Tsuchiya and colleagues, using an ELISA dsDNA) in antinuclear antibody (ANA)-positive type 1 autobased on a similar substrate, found anti-dsDNA in 48% of immune hepatitis, sera from 53 patients were tested by patients with autoimmune hepatitis and 17% of patients with enzyme immunosorbent assay (ELISA) and indirect immunoprimary biliary cirrhosis. 9 Testing of the same sera by an fluorescence using the Crithidia luciliae substrate. Antiindirect immunofluorescence assay based on the kinetoplast dsDNA were detected in 18 patients (34%) by ELISA and 12of Crithidia luciliae, a pure source of dsDNA, disclosed simipatients (23%) by the Crithidia-based assay. Twenty patients lar results. 9 A smaller study from Australia, using an immuwith anti-dsDNA by either assay (38%) had higher serum nofluorescence assay based on Crithidia luciliae, also showed levels of immunoglobulin G (3971 { 270 mg/dL vs. 3201 { a significant serologic overlap with SLE.10 247 mg/dL, P Å .05) than seronegative patients. They also Methodological differences can affect the detection of antihad human leukocyte antigen (HLA) DR4 more commonly dsDNA and the assessment of its clinical significance. Conthan other patients (83% vs. 41%, P Å .006) and normal tamination of the dsDNA substrate with single-stranded DNA subjects (83% vs. 30%, P Å .00007). In contrast to patients (ssDNA) may result in false positive results in some inseropositive by the Crithidia-based assay, those seropositive stances. 5 Differences in antibody avidity and class may also by ELISA failed corticosteroid therapy more commonly (24% influence detection. ELISAs detect antibodies of low avidity vs. 3%, P Å .04). Anti-ssDNA were found in 45 patients that may predominate in diseases other than SLE whereas (85%) and they did not distinguish patients with different the Crithidia assay may detect only high avidity antibodies clinical features or outcomes. We conclude that anti-dsDNA of greater pathogenic importance. outcome to determine the clinical pertinence of the findings and we evaluate the association between antibody expression Antibodies to double-stranded DNA (anti-dsDNA) have a and the known genetic risk factors for type 1 autoimmune high specificity for the diagnosis of systemic lupus erythema-hepatitis. We also determine the frequency of antibodies to tosus (SLE) and they correlate closely with disease activity.

show abstract

“…may also have anti-dsDNA and the specificity of these antibodies for SLE has been challenged. [8][9][10] …”

mentioning

confidence: 99%

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis

Czaja

¹

1997

View full text Add to dashboard Cite

dsDNA were shown in 64% of patients with autoimmune To determine the significance of antibodies to singlehepatitis, 46% with cryptogenic hepatitis, and 43% with stranded (anti-ssDNA) and double-stranded DNA (antichronic hepatitis B. 8 Tsuchiya and colleagues, using an ELISA dsDNA) in antinuclear antibody (ANA)-positive type 1 autobased on a similar substrate, found anti-dsDNA in 48% of immune hepatitis, sera from 53 patients were tested by patients with autoimmune hepatitis and 17% of patients with enzyme immunosorbent assay (ELISA) and indirect immunoprimary biliary cirrhosis. 9 Testing of the same sera by an fluorescence using the Crithidia luciliae substrate. Antiindirect immunofluorescence assay based on the kinetoplast dsDNA were detected in 18 patients (34%) by ELISA and 12of Crithidia luciliae, a pure source of dsDNA, disclosed simipatients (23%) by the Crithidia-based assay. Twenty patients lar results. 9 A smaller study from Australia, using an immuwith anti-dsDNA by either assay (38%) had higher serum nofluorescence assay based on Crithidia luciliae, also showed levels of immunoglobulin G (3971 { 270 mg/dL vs. 3201 { a significant serologic overlap with SLE.10 247 mg/dL, P Å .05) than seronegative patients. They also Methodological differences can affect the detection of antihad human leukocyte antigen (HLA) DR4 more commonly dsDNA and the assessment of its clinical significance. Conthan other patients (83% vs. 41%, P Å .006) and normal tamination of the dsDNA substrate with single-stranded DNA subjects (83% vs. 30%, P Å .00007). In contrast to patients (ssDNA) may result in false positive results in some inseropositive by the Crithidia-based assay, those seropositive stances. 5 Differences in antibody avidity and class may also by ELISA failed corticosteroid therapy more commonly (24% influence detection. ELISAs detect antibodies of low avidity vs. 3%, P Å .04). Anti-ssDNA were found in 45 patients that may predominate in diseases other than SLE whereas (85%) and they did not distinguish patients with different the Crithidia assay may detect only high avidity antibodies clinical features or outcomes. We conclude that anti-dsDNA of greater pathogenic importance. outcome to determine the clinical pertinence of the findings and we evaluate the association between antibody expression Antibodies to double-stranded DNA (anti-dsDNA) have a and the known genetic risk factors for type 1 autoimmune high specificity for the diagnosis of systemic lupus erythema-hepatitis. We also determine the frequency of antibodies to tosus (SLE) and they correlate closely with disease activity.

show abstract

“…Matsumoto's autopsy registry review of 1468 patients suggested an incidence of chronic hepatitis in 2.4% of SLE patients with 1.1% progressing to cirrhosis and 0.8% developing fibrosis [145]. High titers of double stranded DNA, LE cells, anti-ribosomal P antibodies and a more aggressive disease process are noted risk factors for developing chronic hepatitis [144,146,147]. Treatment of hepatic function abnormalities linked purely to generalized lupus activity should be treated with steroids.…”

Section: Liver Function Test Abnormalitiesmentioning

confidence: 99%

The Gastrointestinal Manifestations of Systemic Lupus Erythematosus: A Survey of the Literature

Schulz¹,

Derk²

2009

TOAUTOJ

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is an autoimmune disease associated with auto-antibody production and resulting widespread inflammation that has potential to affect and damage many organ systems. Gastrointestinal manifestations of SLE are well documented in the literature but the exact extent and frequency of their presence is likely grossly underestimated. Patients present with vague complaints such as abdominal pain and nausea with non-specific physical exam findings and inconclusive diagnostic tests and serologic analysis. Recent research has helped to better clarify these manifestations of SLE and has demonstrated distinct involvement of almost every portion of the GI tract. This article is based upon an exhaustive review of the literature from 1976 to present date and summarizes the major advances in the identification and differentiation of gastrointestinal incarnations related to systemic lupus erythematosus. The review also encompasses theories of etiology of the various manifestations, summarizes accepted and experimental treatment regimens, and highlights the differential diagnosis of each presented topic, including disorders of the oropharynx, esophagus, stomach, small and large intestine, liver and gallbladder and beyond.

show abstract

Frequency and significance of antibody to double-stranded DNA in chronic active hepatitis

Cited by 29 publications

References 27 publications

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis

Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis

The Gastrointestinal Manifestations of Systemic Lupus Erythematosus: A Survey of the Literature

Contact Info

Product

Resources

About